title: Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
abstract: BACKGROUND
  Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.
  
  
  OBJECTIVE
  To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.
  
  
  METHODS
  Randomized double-blind controlled cross-over trial.
  
  
  METHODS
  Community and hospital-based.
  
  
  METHODS
  Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.
  
  
  METHODS
  Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.
  
  
  METHODS
  (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.
  
  
  RESULTS
  Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).
  
  
  CONCLUSIONS
  Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
authors.affiliation: Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Wynne
authors.forename: A J
authors.initials: AJ
authors.lastname: Park
authors.forename: C J
authors.initials: CJ
authors.lastname: Small
authors.forename: K
authors.initials: K
authors.lastname: Meeran
authors.forename: M A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: G S
authors.initials: GS
authors.lastname: Frost
authors.forename: S R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D018592:Cross-Over Studies; D004311:Double-Blind Method; D002149:Energy Intake / Q000187:drug effects*; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D050177:Overweight / Q000187:drug effects; D053772:Oxyntomodulin / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D012646:Self Administration
chemical_list: D019440:Anti-Obesity Agents; D007328:Insulin; D053772:Oxyntomodulin